Basics and principles of radiopharmaceuticals for PET/CT

被引：84
|
作者：
Wadsak, W. [1 ]
Mitterhauser, M. [1 ,2 ]
机构：
[1] Med Univ Vienna, Dept Nucl Med, Vienna, Austria
[2] Univ Vienna, Dept Pharmaceut Technol & Biopharmaceut, A-1010 Vienna, Austria
来源：
EUROPEAN JOURNAL OF RADIOLOGY | 2010年 / 73卷 / 03期
关键词：
Radiopharmaceutical; Tracer; Radiopharmacology; Radiochemistry; POSITRON-EMISSION-TOMOGRAPHY; PROLIFERATION IN-VIVO; PROSTATE-CANCER; NO-CARRIER; F-18-LABELED; 2-DEOXY-2-FLUORO-D-GLUCOSE; NUCLEOPHILIC-SUBSTITUTION; F-18; FLUOROMISONIDAZOLE; GA-68-LABELED PEPTIDES; CELLULAR PROLIFERATION; CONVENIENT SYNTHESIS;
D O I：
10.1016/j.ejrad.2009.12.022
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The presented review provides general background on PET radiopharmaceuticals for oncological applications. Special emphasis is put on radiopharmacological, radiochemical and regulatory aspects. This review is not meant to give details on all different PET tracers in depth but to provide insights into the general principles coming along with their preparation and use. The PET tracer plays a pivotal role because it provides the basis both for image quality and clinical interpretation. It is composed of the radionuclide (signaller) and the molecular vehicle which determines the (bio-)chemical properties (e.g. binding characteristics, metabolism, elimination rate). (C) 2010 Published by Elsevier Ireland Ltd.
引用
收藏
页码：461 / 469
页数：9
相关论文
共 50 条
  • [41] The search for consistency in the manufacture of PET radiopharmaceuticals
    Ronald D. Finn
    Annals of Nuclear Medicine, 1999, 13 : 379 - 382
  • [42] PET RADIOPHARMACEUTICALS VIA REDUCTIVE CARBOXYLATION
    RAM, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1990, 200 : 27 - NUCL
  • [43] PET radiopharmaceuticals dispensing unit.
    Mishani, E
    Laki, D
    Wajnblum, D
    Chisin, R
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 378P - 378P
  • [44] Back to basics to recycle PET
    不详
    MATERIALS WORLD, 1999, 7 (10) : 606 - 606
  • [45] Current and Future Cardiovascular PET Radiopharmaceuticals
    Al-Haddad, Rami
    Ismailani, Uzair S.
    Rotstein, Benjamin H.
    PET CLINICS, 2019, 14 (02) : 293 - +
  • [46] Lymphoma basics in pet practice
    Polton, Gerry
    IRISH VETERINARY JOURNAL, 2008, 61 (08) : 539 - 542
  • [47] Radiopharmacy and radiopharmaceuticals in Brazil: sanitaries aspects related to a project of an industry of PET radiopharmaceuticals
    Oliveira, Ralph Santos
    Benevides, Clayton Augusto
    Hwang, Suy Ferreira
    Camara Salvi, Roberto Paulo
    Teixeira Ricarte de Freitas, Ione Maria Acioly
    REVISTA BRASILEIRA DE CIENCIAS FARMACEUTICAS, 2008, 44 (02): : 181 - 184
  • [48] Patient specific treatment planning for systemically administered radiopharmaceuticals using PET/CT and Monte Carlo simulation
    Grudzinski, J. J.
    Yoriyaz, H.
    DeLuca, P. M., Jr.
    Weichert, J. P.
    APPLIED RADIATION AND ISOTOPES, 2010, 68 (01) : 59 - 65
  • [49] Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma
    Nyakale, Nozipho
    Filippi, Luca
    Aldous, Colleen
    Sathekge, Mike
    CANCERS, 2023, 15 (07)
  • [50] PET Oncological Radiopharmaceuticals: Current Status and Perspectives
    Lin, Mai
    Coll, Ryan P.
    Cohen, Allison S.
    Georgiou, Dimitra K.
    Manning, Henry Charles
    MOLECULES, 2022, 27 (20):
12345